San Diego-based Dexcom, a leading diabetes technology company known for its wearable glucose monitors, is expanding its NIL ...

Biolinq received $100 million in a Series C funding round to bring its wearable for patients with diabetes to market, the ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Biolinq has raised $100 million in venture capital financing to help complete the development of its wearable glucose ...

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

Scientists have identified a simple, noninvasive method for assessing blood glucose regulation using continuous glucose monitoring (CGM) data. Their approach, which tracks glucose fluctuations, ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

The US Food and Drug Administration has cleared the latest version to last 5 days longer than previously for adult users.

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System ... to the patient’s Apple Watch. Automated activity logging ...